ArticlePharmaceuticals (Basel, Switzerland)2012
Epigenetic mechanisms and therapeutic perspectives for neurodevelopmental disorders.
Article in Pharmaceuticals (Basel, Switzerland), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 28 citations in OpenAlex.
- Beyond the Genotype: A Multi-Omic Analysis of APOEe4's Role in Alzheimer's Disease.bioRxiv : the preprint server for biology · 2025Article
- The MNK-SYNGAP1 axis in specific learning disorder: gene expression pattern and new perspectives.European journal of pediatrics · 2025Article
- Implications of petrochemical exposure and epigenetic alterations on human health.Frontiers in toxicology · 2025Review
- Interaction of Heavy Metal Lead with Gut Microbiota: Implications for Autism Spectrum Disorder.Biomolecules · 2023Review
- Natural Bioactive Products as Epigenetic Modulators for Treating Neurodegenerative Disorders.Pharmaceuticals (Basel, Switzerland) · 2023Review
- DNA Methylation of the Oxytocin Receptor Across Neurodevelopmental Disorders.Journal of autism and developmental disorders · 2021Article
- Metabolic disorder in Alzheimer's disease.Metabolic brain disease · 2021Review
- Pharmacoepigenomic Interventions as Novel Potential Treatments for Alzheimer's and Parkinson's Diseases.International journal of molecular sciences · 2018Review
- Epigenetics of Aging and Alzheimer's Disease: Implications for Pharmacogenomics and Drug Response.International journal of molecular sciences · 2015Review
- Personalizing health care: feasibility and future implications.BMC medicine · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The number of children with mild neurodevelopmental disorders, such as autism, has been recently increasing in advanced countries. This increase is probably caused by environmental factors rather than genetic factors, because it is unlikely that genetic mutation rates suddenly increased within a short period. Epigenetics is a mechanism that regulates gene expression, depending not on the underlying DNA sequence but on the chemical modifications of DNA and histone proteins. Because mental stress can alter the epigenetic status in neuronal cells, environmental factors may alter brain function through epigenetic changes. However, one advantage of epigenetic changes is their reversibility. Therefore, diseases due to abnormal epigenetic regulation are theoretically treatable. In fact, several drugs for treating mental diseases are known to have restoring effects on aberrant epigenetic statuses, and a novel therapeutic strategy targeting gene has been developed. In this review, we discuss epigenetic mechanisms of congenital and acquired neurodevelopmental disorders, drugs with epigenetic effects, novel therapeutic strategies for epigenetic diseases, and future perspectives in epigenetic medicine.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.